Advertisement

Nicotine

  • Freda Patterson
  • Robert A. Schnoll
  • Caryn Lerman
Chapter

Abstract

Tobacco use is a leading cause of morbidity and mortality across the world. Cessation rates in developed countries such as the United States have stalled, while smoking uptake rates in the developing nations of the world, such as China and India, are on the rise. Given the highly addictive nature of nicotine, along with the multifaceted etiology of this addiction that includes biological and behavioral determinants, identifying effective treatments remains a challenge to smoking cessation practitioners. Current Food and Drug Administration-approved treatments for nicotine dependence include nicotine replacement therapies (NRTs), bupropion, and varenicline. Although these first-line smoking cessation therapies significantly improve a smoker’s likelihood of quitting, a majority of smokers fail to maintain long-term abstinence using these treatments. To curtail the growing global health epidemic of nicotine dependence, continued work to identify biological and behavioral variables that predict treatment response as well as the identification and appropriate dissemination of new treatments is needed. This two-pronged approach could potentially allow clinicians to move toward a more personalized, cost-effective model for the prescription of smoking cessation therapies that could help more treatment-seeing smokers achieve long-term abstinence.

Keywords

Dependence Tobacco Nicotine Addiction Public policy Pharmacogenetics 

References

  1. 1.
    Abrams D, Monti P, Pinto R, Elder J, Brown R, Jacobus S (1987) Psychosocial stress and coping in smokers who relapse or quit. Health Psychol 6:289–303PubMedCrossRefGoogle Scholar
  2. 2.
    Adan A, Prat G, Sanchez-Turet M (2004) Effects of nicotine dependence on diurnal variations of subjective activation and mood. Addiction 99:1599–1607PubMedCrossRefGoogle Scholar
  3. 3.
    Ahijevych K, Gillespie J (1997) Nicotine dependence and smoking topography among black and white women. Res Nurs Health 20:505–514PubMedCrossRefGoogle Scholar
  4. 4.
    Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS (2002) Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288:468–474PubMedCrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. American Psychiatric Association, Washington, DCGoogle Scholar
  6. 6.
    Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr (2008) Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 103:687–694PubMedCrossRefGoogle Scholar
  7. 7.
    APA (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  8. 8.
    APA, Substance-Related Disorders. (1994) DSM IV: diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington DC, pp 175–272Google Scholar
  9. 9.
    Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395–401PubMedGoogle Scholar
  10. 10.
    Balfour DJ, Wright AE, Benwell ME, Birrell CE (2000) The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113:73–83PubMedCrossRefGoogle Scholar
  11. 11.
    Barnett PG, Wong W, Hall S (2008) The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression. Addiction 103:834–840PubMedCrossRefGoogle Scholar
  12. 12.
    Benowitz N. (1994) Acute biological effects of nicotine and its metabolites. In: Clark PBS et al (eds) Effects of nicotine on biological systems II. Springer, New York, pp 9–16Google Scholar
  13. 13.
    Benowitz NL (2002) Smoking cessation trials targeted to racial and economic minority groups. JAMA 288:497–499PubMedCrossRefGoogle Scholar
  14. 14.
    Benowitz NL (2008) Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med 121:S3–S10PubMedCrossRefGoogle Scholar
  15. 15.
    Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H et al (2008) Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 13:368–373PubMedCrossRefGoogle Scholar
  16. 16.
    Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P et al (2007) Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 61:111–118PubMedCrossRefGoogle Scholar
  17. 17.
    Beuten J, Payne TJ, Ma JZ, Li MD (2006) Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 31:675–684PubMedCrossRefGoogle Scholar
  18. 18.
    Bierut L, Rice J, Edenberg H, Goate A, Foroud T, Cloninger C (2000) Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 90:299–302PubMedCrossRefGoogle Scholar
  19. 19.
    Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF et al (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16:24–35PubMedCrossRefGoogle Scholar
  20. 20.
    Blondal T, Franzon M, Westin A (1997) A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respiratory J 10:1585–1590CrossRefGoogle Scholar
  21. 21.
    Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A (1999) Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. Br Med J 318:285–288CrossRefGoogle Scholar
  22. 22.
    Bolin LJ, Follette WC, Antonuccio DO, Krumpe P (1999) Transdermal nicotine: the long and short of it. Psychol Addict Behav 13:152–156CrossRefGoogle Scholar
  23. 23.
    Borrelli B, Bock B, King T, Pinto B, Marcus BH (1996) The impact of depression on smoking cessation in women. Am J Prev Med 12:378–387PubMedGoogle Scholar
  24. 24.
    Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, DePue JD, Murphy C et al (1996) Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry 57:534–538PubMedCrossRefGoogle Scholar
  25. 25.
    Borrelli B, Hogan JW, Bock B, Pinto B, Roberts M, Marcus B (2002) Predictors of quitting and dropout among women in a clinic-based smoking cessation program. Psychol Addict Behav 16:22–27PubMedCrossRefGoogle Scholar
  26. 26.
    Boutou AK, Tsiata EA, Pataka A, Kontou PK, Pitsiou GG, Argyropoulou P (2008) Smoking cessation in clinical practice: predictors of six-month continuous abstinence in a sample of Greek smokers. Prim Care Respir J 17:32–38PubMedCrossRefGoogle Scholar
  27. 27.
    Breslau N, Kilbey M, Andreski P (1991) Nicotine dependence, major depression, and anxiety in young adults. Archiv Gen Psychiatry 48:1069–1074CrossRefGoogle Scholar
  28. 28.
    Breteler MH, Hilberink SR, Zeeman G, Lammers SM (2004) Compulsive smoking: the development of a Rasch homogeneous scale of nicotine dependence. Addict Behav 29:199–205PubMedCrossRefGoogle Scholar
  29. 29.
    Bricker JB, Peterson AV Jr, Leroux BG, Andersen MR, Rajan KB, Sarason IG (2006) Prospective prediction of children’s smoking transitions: role of parents’ and older siblings’ smoking. Addiction 101:128–136PubMedCrossRefGoogle Scholar
  30. 30.
    Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D et al (2006) Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63:907–915PubMedCrossRefGoogle Scholar
  31. 31.
    Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J (2006) Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res Hum Genet 9:64–72PubMedCrossRefGoogle Scholar
  32. 32.
    Brown RA, Kahler CW, Niaura R, Abrams DB, Sales SD, Ramsey SE et al (2001) Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol 69:471–480PubMedCrossRefGoogle Scholar
  33. 33.
    Burgess ES, Brown RA, Kahler CW, Niaura R, Abrams DB, Goldstein MG et al (2002) Patterns of change in depressive symptoms during smoking cessation: who’s at risk for relapse? J Consult Clin Psychol 70:356–361PubMedCrossRefGoogle Scholar
  34. 34.
    Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ et al (1998) Racial and ethnic differences in serum cotinine levels of cigarette smokers: third national health and nutrition examination survey, 1988–1991. JAMA 280:135–139PubMedCrossRefGoogle Scholar
  35. 35.
    Carter BL, Tiffany ST (1999) Meta-analysis of cue-reactivity in addiction research. Addiction 94:327–340PubMedCrossRefGoogle Scholar
  36. 36.
    Centers for Disease Control (2007) Cigarette smoking among adults—United States, 2006. MMWR Morb Mortal Wkly Rep 56:157–1161Google Scholar
  37. 37.
    Centers for Disease Control and Prevention (2005) Cigarette smoking among adults—United States 2004. Morb Mortal Wkly Rep 54:1121–1124Google Scholar
  38. 38.
    Centers for Disease Control and Prevention (2001) Women and smoking: a report by the surgeon general. Department of Health and Human Services, Rockville, MDGoogle Scholar
  39. 39.
    Cepeda-Benito A (1993) Meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. J Consult Clin Psychol 61:822–830PubMedCrossRefGoogle Scholar
  40. 40.
    Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F (1998) Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 9:3097–3101PubMedCrossRefGoogle Scholar
  41. 41.
    Choi JH, Dresler CM, Norton MR, Strahs KR (2003) Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5:635–644PubMedCrossRefGoogle Scholar
  42. 42.
    Choi WS, Patten CA, Gillin JC, Kaplan RM, Pierce JP (1997) Cigarette smoking predicts development of depressive symptoms among U.S. adolescents. Ann Behav Med 19:42–50PubMedCrossRefGoogle Scholar
  43. 43.
    Clark PI, Gautam S, Gerson LW (1996) Effect of menthol cigarettes on biochemical markers of smoke exposure among black and white smokers. Chest 110:1194–1198PubMedCrossRefGoogle Scholar
  44. 44.
    Coe JW, Vetelino MG, Bashore CG, Wirtz MC, Brooks PR, Arnold EP et al (2005) In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 15:2974–2979PubMedCrossRefGoogle Scholar
  45. 45.
    Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J et al (2005) Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 15:393–398PubMedCrossRefGoogle Scholar
  46. 46.
    Comings D, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D (1996) The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6:73–79PubMedCrossRefGoogle Scholar
  47. 47.
    Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133–141PubMedGoogle Scholar
  48. 48.
    Cousins MS, Stamat HM, de Wit H (2001) Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243–253CrossRefGoogle Scholar
  49. 49.
    Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL et al (2003) Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 5:181–187PubMedCrossRefGoogle Scholar
  50. 50.
    Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR (1995) High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 274:1353–1358PubMedCrossRefGoogle Scholar
  51. 51.
    Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446PubMedCrossRefGoogle Scholar
  52. 52.
    Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E et al (1999) The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 28:113–118PubMedCrossRefGoogle Scholar
  53. 53.
    Davenport KE, Houdi AA, Van Loon GR (1990) Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 113:40–46PubMedCrossRefGoogle Scholar
  54. 54.
    David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR et al (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9:821–833PubMedCrossRefGoogle Scholar
  55. 55.
    David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC (2007) The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tobacco Res 9(2):225–231Google Scholar
  56. 56.
    DiFranza JR, Wellman RJ, Sargent JD, Weitzman M, Hipple BJ, Winickoff JP (2006) Tobacco promotion and the initiation of tobacco use: assessing the evidence for causality. Pediatrics 117: e1237–e1248PubMedCrossRefGoogle Scholar
  57. 57.
    Drobes DJ, Tiffany ST (1997) Induction of smoking urge through imaginal and in vivo procedures: physiological and self-report manifestations. J Abnorm Psychol 106:15–25PubMedCrossRefGoogle Scholar
  58. 58.
    Escobedo LG, Kirch DG, Anda RF (1996) Depression and smoking initiation among US Latinos. Addiction 91:113–119PubMedCrossRefGoogle Scholar
  59. 59.
    Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491PubMedCrossRefGoogle Scholar
  60. 60.
    Fagerstrom KO, Heatherton TF, Kozlowski LT (1990) Nicotine addiction and its assessment. Ear, Nose, Throat J 69:763–765Google Scholar
  61. 61.
    Feng Y, Niu T, Xing H, Xu X, Chen C, Peng S et al (2004) A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 75:112–121PubMedCrossRefGoogle Scholar
  62. 62.
    Fiore M, Smith S, Jorenby D, Baker T (1994) The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. J Am Med Assoc 271:1940–1947CrossRefGoogle Scholar
  63. 63.
    Fiore M, Bailey W, Cohen S, Dorfman S, Goldstein M, Gritz E et al (2000) Treating tobacco use and dependence: a clinical practical guideline. US Department of Health and Human Services, Public Health ServiceGoogle Scholar
  64. 64.
    Fiore MC (2000) Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respiratory Care 45:1196–1199PubMedGoogle Scholar
  65. 65.
    Forrester K, Biglan A, Severson HH, Smolkowski K (2007) Predictors of smoking onset over two years. Nicotine Tob Res 9:1259–1267PubMedCrossRefGoogle Scholar
  66. 66.
    Foulds J, Steinberg MB, Williams JM, Ziedonis DM (2006) Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 25:59–71PubMedCrossRefGoogle Scholar
  67. 67.
    Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O’Brien CP et al (2008) Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Womens Health (Larchmt) 17:287–292CrossRefGoogle Scholar
  68. 68.
    Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B et al (2000) Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res 2:53–63PubMedCrossRefGoogle Scholar
  69. 69.
    Ginsberg D, Hall SM, Reus VI, Munoz RF (1995) Mood and depression diagnosis in smoking cessation. Exp Clin Psychopharmacol 3:389–395CrossRefGoogle Scholar
  70. 70.
    Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE et al (1990) Smoking, smoking cessation, and major depression. JAMA 264:1546–1549PubMedCrossRefGoogle Scholar
  71. 71.
    Glassman AH, Covey LS, Stetner F, Rivelli S (2001) Smoking cessation and the course of major depression: a follow-up study. Lancet 357:1929–1932PubMedCrossRefGoogle Scholar
  72. 72.
    Glavas D, Rumboldt Z (2003) Smoking cessation using the transdermal nicotine system. Lijec Vjesn 125:8–12PubMedGoogle Scholar
  73. 73.
    Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95:9991–9996PubMedCrossRefGoogle Scholar
  74. 74.
    Gonzales D, Bjornson W, Durcan MJ, White JD, Johnston JA, Buist AS et al (2002) Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prevent Med 22:234–239CrossRefGoogle Scholar
  75. 75.
    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55PubMedCrossRefGoogle Scholar
  76. 76.
    Goodman E, Capitman J (2000) Depressive symptoms and cigarette smoking among teens. Pediatrics 106:748–755PubMedCrossRefGoogle Scholar
  77. 77.
    Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999) Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159:2033–2038PubMedCrossRefGoogle Scholar
  78. 78.
    Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL et al (1996) Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 64:1003–1009PubMedCrossRefGoogle Scholar
  79. 79.
    Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT et al (1998) Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–690PubMedCrossRefGoogle Scholar
  80. 80.
    Halpern MT, Dirani R, Schmier JK (2007) The cost effectiveness of varenicline for smoking cessation. Manag Care Interface 20:18–25PubMedGoogle Scholar
  81. 81.
    Harris RE, Zang EA, Anderson JI, Wynder EL (1993) Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 22:592–599PubMedCrossRefGoogle Scholar
  82. 82.
    Heatherton T, Kozlowski L, Frecker R, Fagerstrom K (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addiction 86:1119–1127CrossRefGoogle Scholar
  83. 83.
    Heinz A, Goldman D, Gallinat J, Schumann G, Puls I (2004) Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. Psychopharmacology (Berl) 174:561–570CrossRefGoogle Scholar
  84. 84.
    Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C (2008) Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 8(6):391–399Google Scholar
  85. 85.
    Henningfield J, Keenan R (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743–750PubMedCrossRefGoogle Scholar
  86. 86.
    Hjalmarson A, Franzon M, Westin A, Wiklund O (1994) Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 154:2567–2572PubMedCrossRefGoogle Scholar
  87. 87.
    Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O (1997) The nicotine inhaler in smoking cessation. Arch Intern Med 157:1721–1728PubMedCrossRefGoogle Scholar
  88. 88.
    Hoogendoorn M, Welsing P, Rutten-van Molken MP (2008) Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 24:51–61PubMedGoogle Scholar
  89. 89.
    Hudmon KS, Marks JL, Pomerleau CS, Bolt DM, Brigham J, Swan GE (2003) A multidimensional model for characterizing tobacco dependence. Nicotine Tob Res 5:655–664PubMedCrossRefGoogle Scholar
  90. 90.
    Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML (1989) Nicotine vs placebo gum in general medical practice. JAMA 261:1300–1305PubMedCrossRefGoogle Scholar
  91. 91.
    Hughes JR, Goldstein MG, Hurt RD, Shiffman S (1999) Recent advances in the pharmacotherapy of smoking. JAMA 281:72–76PubMedCrossRefGoogle Scholar
  92. 92.
    Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE et al (1999) Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1:169–174PubMedCrossRefGoogle Scholar
  93. 93.
    Hughes JR (2003) Motivating and helping smokers to stop smoking. J Gen Intern Med 18:1053–1057PubMedCrossRefGoogle Scholar
  94. 94.
    Hughes JR, Oliveto AH, Riggs R, Kenny M, Liguori A, Pillitteri JL et al (2004) Concordance of different measures of nicotine dependence: two pilot studies. Addict Behav 29:1527–1539PubMedCrossRefGoogle Scholar
  95. 95.
    Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev CD000031Google Scholar
  96. 96.
    Hukkanen J, Jacob P 3rd, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115PubMedCrossRefGoogle Scholar
  97. 97.
    Hurt R, Dale L, Croghan G, Croghan I, Gomez-Dahl L, Offord K (1998) Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin Proc 73:118–125PubMedCrossRefGoogle Scholar
  98. 98.
    Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP et al (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 271:595–600PubMedCrossRefGoogle Scholar
  99. 99.
    Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202PubMedCrossRefGoogle Scholar
  100. 100.
    Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ et al (2002) Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 27:493–507PubMedCrossRefGoogle Scholar
  101. 101.
    Hutchison KE, LaChance H, Niaura R, Bryan A, Smolen A (2002) The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnormal Psychol 111:134–143CrossRefGoogle Scholar
  102. 102.
    Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL et al (2007) CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64:1078–1086PubMedCrossRefGoogle Scholar
  103. 103.
    Jackson KC, 2nd, Nahoopii R, Said Q, Dirani R, Brixner D (2007) An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med 49:453–460CrossRefGoogle Scholar
  104. 104.
    John U, Meyer C, Hapke U, Rumpf HJ, Schumann A (2004) Nicotine dependence, quit attempts, and quitting among smokers in a regional population sample from a country with a high prevalence of tobacco smoking. Prev Med 38:350–358PubMedCrossRefGoogle Scholar
  105. 105.
    Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA (2005) Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 165:1600–1605PubMedCrossRefGoogle Scholar
  106. 106.
    Johnson BA (2006) New weapon to curb smoking: no more excuses to delay treatment. Arch Intern Med 166:1547–1550PubMedCrossRefGoogle Scholar
  107. 107.
    Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF et al (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:83–90PubMedCrossRefGoogle Scholar
  108. 108.
    Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafo MR (2007) Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 16:1065–1069PubMedCrossRefGoogle Scholar
  109. 109.
    Jones SE, Sharp DJ, Husten CG, Crossett LS (2002) Cigarette acquisition and proof of age among US high school students who smoke. Tob Control 11:20–25PubMedCrossRefGoogle Scholar
  110. 110.
    Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT et al (1995) Varying nicotine patch dose and type of smoking cessation counseling. JAMA 274:1347–1352PubMedCrossRefGoogle Scholar
  111. 111.
    Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedCrossRefGoogle Scholar
  112. 112.
    Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE et al (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama 296:56–63PubMedCrossRefGoogle Scholar
  113. 113.
    Karoum F, Egan MF, Wyatt RJ (1994) Selective reduction in dopamine turnover in the rat frontal cortex and hypothalamus during withdrawal from repeated cocaine exposure. Eur J Pharmacol 254:127–132PubMedCrossRefGoogle Scholar
  114. 114.
    Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC (1993) Smoking and major depression. A causal analysis. Arch Gen Psychiatry 50:36–43PubMedCrossRefGoogle Scholar
  115. 115.
    Kendler KS, Thornton LM, Pedersen NL (2000) Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psychiatry 57:886–892PubMedCrossRefGoogle Scholar
  116. 116.
    Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB (1994) Predicting smoking cessation. Who will quit with and without the nicotine patch. Jama 271:589–594PubMedCrossRefGoogle Scholar
  117. 117.
    Killen JD, Fortmann SP, Newman B, Varady A (1990) Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 58:85–92PubMedCrossRefGoogle Scholar
  118. 118.
    Killen JD, Fortmann SP, Varady A, Kraemer HC (2002) Do men outperform women in smoking cessation trials? Maybe, but not by much. Exp Clin Psychopharmacol 10:295–301PubMedCrossRefGoogle Scholar
  119. 119.
    Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Arredondo C, Cromp D et al (2006) Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol 74:286–294PubMedCrossRefGoogle Scholar
  120. 120.
    Kim H, Clark PI (2006) Cigarette smoking transition in females of low socioeconomic status: impact of state, school, and individual factors. J Epidemiol Community Health 60(Suppl 2):13–19PubMedGoogle Scholar
  121. 121.
    Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58PubMedCrossRefGoogle Scholar
  122. 122.
    Koopmans JR, Slutske WS, Heath AC, Neale MC, Boomsma DI (1999) The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins. Behav Genet 29:383–393PubMedCrossRefGoogle Scholar
  123. 123.
    Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G (1995) Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prevent Med 24:41–47CrossRefGoogle Scholar
  124. 124.
    Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T (1994) Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend 34:211–216PubMedCrossRefGoogle Scholar
  125. 125.
    Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E et al (2006) CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 6:115–119PubMedCrossRefGoogle Scholar
  126. 126.
    Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C et al (2007) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62:635–641PubMedCrossRefGoogle Scholar
  127. 127.
    Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF (2007) CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 16:1312–1314PubMedCrossRefGoogle Scholar
  128. 128.
    Lerman C, Audrain J, Orleans CT, Boyd R, Gold K, Main D et al (1996) Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav 21:9–19PubMedCrossRefGoogle Scholar
  129. 129.
    Lerman C, Shields PG, Audrain J, Main D, Cobb B, Boyd NR et al (1998) The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prevent 7:253–255Google Scholar
  130. 130.
    Lerman C, Caporaso N, Audrain J, Main D, Bowman E, Lockshin B et al (1999) Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18:14–20PubMedCrossRefGoogle Scholar
  131. 131.
    Lerman C, Shields P, Wileyto E, Audrain J, Pinto A, Hawk L et al (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:627–634PubMedCrossRefGoogle Scholar
  132. 132.
    Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A et al (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541–548PubMedCrossRefGoogle Scholar
  133. 133.
    Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP et al (2004) Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl) 174:571–577CrossRefGoogle Scholar
  134. 134.
    Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J et al (2004) Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 140:426–433PubMedGoogle Scholar
  135. 135.
    Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S et al (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184–192PubMedCrossRefGoogle Scholar
  136. 136.
    Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F et al (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231–242PubMedGoogle Scholar
  137. 137.
    Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A et al (2006) Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 79:600–608PubMedCrossRefGoogle Scholar
  138. 138.
    Lerman C, LeSage MG, Perkins KA, O’Malley SS, Siegel SJ, Benowitz NL et al (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6:746–762PubMedCrossRefGoogle Scholar
  139. 139.
    Leventhal AM, Ramsey SE, Brown RA, Lachance HR, Kahler CW (2008) Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res 10:507–517PubMedCrossRefGoogle Scholar
  140. 140.
    Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB (1998) Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev Med 27:296–303PubMedCrossRefGoogle Scholar
  141. 141.
    Li MD, Cheng R, Ma JZ, Swan GE (2003) A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98:23–31PubMedCrossRefGoogle Scholar
  142. 142.
    Li MD, Beuten J, Ma JZ, Payne TJ, Lou XY, Garcia V et al (2005) Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 14:1211–1219PubMedCrossRefGoogle Scholar
  143. 143.
    Liu X, Caggiula AR, Yee SK, Nobuta H, Poland RE, Pechnick RN (2006) Reinstatement of nicotine-seeking behavior by drug-associated stimuli after extinction in rats. Psychopharmacology (Berl) 184:417–425CrossRefGoogle Scholar
  144. 144.
    Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I et al (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202–4210PubMedCrossRefGoogle Scholar
  145. 145.
    Lou XY, Ma JZ, Payne TJ, Beuten J, Crew KM, Li MD (2006) Gene-based analysis suggests association of the nicotinic acetylcholine receptor beta1 subunit (CHRNB1) and M1 muscarinic acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence. Hum Genet 120:381–389PubMedCrossRefGoogle Scholar
  146. 146.
    Lueders KK, Hu S, McHugh L, Myakishev MV, Sirota LA, Hamer DH (2002) Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). Nicotine Tob Res 4:115–125PubMedCrossRefGoogle Scholar
  147. 147.
    Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI (2006) Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 31:52–61PubMedCrossRefGoogle Scholar
  148. 148.
    MacKay J and Eriksen M, The Tobacco Atlas. (2002) The world health organization, GenevaGoogle Scholar
  149. 149.
    Malaiyandi V, Sellers EM, Tyndale RF (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77:145–158PubMedCrossRefGoogle Scholar
  150. 150.
    Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400–409PubMedCrossRefGoogle Scholar
  151. 151.
    Mangold JE, Payne TJ, Ma JZ, Chen G, Li MD (2008) Bitter taste receptor gene polymorphisms are an important factor in the development of nicotine dependence in African Americans. J Med Genet 45:578–582PubMedCrossRefGoogle Scholar
  152. 152.
    Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM et al (2003) Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17:1329–1337PubMedCrossRefGoogle Scholar
  153. 153.
    McBride D, Barrett SP, Kelly JT, Aw A, Dagher A (2006) Effects of expectancy and abstinence on the neural response to smoking cues in cigarette smokers: an fMRI study. Neuropsychopharmacology 31:2728–2738PubMedCrossRefGoogle Scholar
  154. 154.
    McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC et al (2008) A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res 10:717–729PubMedCrossRefGoogle Scholar
  155. 155.
    McClernon FJ, Hiott FB, Huettel SA, Rose JE (2005) Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology 30:1940–1947PubMedCrossRefGoogle Scholar
  156. 156.
    McGue M, Elkins I, Iacono WG (2000) Genetic and environmental influences on adolescent substance use and abuse. Am J Med Genet 96:671–677PubMedCrossRefGoogle Scholar
  157. 157.
    McKinney E, Walton R, Yudkin P, Fuller A, Haldar N, Mant D et al (2000) Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10:483–491PubMedCrossRefGoogle Scholar
  158. 158.
    Mifsud JC, Hernandez L, Hoebel BG (1989) Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 478:365–367PubMedCrossRefGoogle Scholar
  159. 159.
    Millar NS (2003) Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem Soc Trans 31:869–74PubMedCrossRefGoogle Scholar
  160. 160.
    Miranda R, Jr., Rohsenow DJ, Monti PM, Tidey J, Ray L (2008) Effects of repeated days of smoking cue exposure on urge to smoke and physiological reactivity. Addict Behav 33:347–353PubMedCrossRefGoogle Scholar
  161. 161.
    Moolchan ET, Radzius A, Epstein DH, Uhl G, Gorelick DA, Cadet JL et al (2002) The Fagerstrom test for nicotine dependence and the diagnostic interview schedule: do they diagnose the same smokers? Addict Behav 27:101–113PubMedCrossRefGoogle Scholar
  162. 162.
    Morrell HE, Cohen LM, Al’absi M (2008) Physiological and psychological symptoms and predictors in early nicotine withdrawal. Pharmacol Biochem Behav 89:272–278PubMedCrossRefGoogle Scholar
  163. 163.
    Munafo M, Bradburn M, Bowes L, David S (2004) Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res 6:769–776PubMedCrossRefGoogle Scholar
  164. 164.
    Munafo M, Clark T, Johnstone E, Murphy M, Walton R (2004) The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6:583–597PubMedCrossRefGoogle Scholar
  165. 165.
    Munafo M, Roberts K, Johnstone EC, Walton RT, Yidlin P (2005) Association of serotonin transporter gene polymorphism with nicotine dependence. No evidence for an interaction with trait neuroticism. Personality Individual Differences 38:843–850CrossRefGoogle Scholar
  166. 166.
    Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C (2006) Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 15:398–400PubMedCrossRefGoogle Scholar
  167. 167.
    Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC (2007) Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J 7:353–361PubMedCrossRefGoogle Scholar
  168. 168.
    Munafo MR, Hitsman B, Rende R, Metcalfe C, Niaura R (2008) Effects of progression to cigarette smoking on depressed mood in adolescents: evidence from the national longitudinal study of adolescent health. Addiction 103:162–171PubMedCrossRefGoogle Scholar
  169. 169.
    Munafo MR, Johnstone EC, Guo B, Murphy MF, Aveyard P (2008) Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet Genomics 18:121–128PubMedCrossRefGoogle Scholar
  170. 170.
    Muramoto ML, Ranger-Moore J, Leischow SJ (2003) Efficacy of oral transmucosal nicotine lozenge for suppression of withdrawal symptoms in smoking abstinence. Nicotine Tob Res 5:223–230PubMedCrossRefGoogle Scholar
  171. 171.
    Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee do H et al (2007) Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. J Korean Med Sci 22:1065–1070PubMedCrossRefGoogle Scholar
  172. 172.
    Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR (2007) Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 29:1040–1056PubMedCrossRefGoogle Scholar
  173. 173.
    Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8:1445–1449PubMedCrossRefGoogle Scholar
  174. 174.
    Niaura R, Abrams D, Demuth B, Pinto R, Monti P (1989) Responses to smoking-related stimuli and early relapse to smoking. Addict Behav 14:419–428PubMedCrossRefGoogle Scholar
  175. 175.
    Niaura R, Britt DM, Borrelli B, Shadel WG, Abrams DB, Goldstein MG (1999) History and symptoms of depression among smokers during a self-initiated quit attempt. Nicotine Tob Res 1:251–257PubMedCrossRefGoogle Scholar
  176. 176.
    Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M et al (2005) Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction 100:1720–1730PubMedCrossRefGoogle Scholar
  177. 177.
    Nollen N, Ahluwalia JS, Mayo MS, Richter K, Choi WS, Okuyemi KS et al (2007) A randomized trial of targeted educational materials for smoking cessation in African Americans using transdermal nicotine. Health Educ Behav 34:911–927PubMedCrossRefGoogle Scholar
  178. 178.
    O’Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G et al (2007) Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 17:61–67PubMedCrossRefGoogle Scholar
  179. 179.
    Osler M, Holst C, Prescott, E, Sorensen T (2001) Influence of genes and family environment on adult smoking behavior assessed in an adoption study. Genetic Epidemiol 21:193–200CrossRefGoogle Scholar
  180. 180.
    Patterson F, Schnoll R, Wileyto E, Pinto A, Epstein L, Shields P et al (2008) Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 84(3):320–325Google Scholar
  181. 181.
    Perez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL (1998) Nicotine metabolism and intake in black and white smokers. JAMA 280:152–156PubMedCrossRefGoogle Scholar
  182. 182.
    Perkins K, Grobe J, D’Amicao D, Fonte C, Wilson A, Stiller R (1996) Low-dose nicotine nasal spray use and effects during initial smoking cessation. Exp Clin Psychopharmacol 4:157–165CrossRefGoogle Scholar
  183. 183.
    Perkins KA, Epstein LH, Grobe J, Fonte C (1994) Tobacco abstinence, smoking cues, and the reinforcing value of smoking. Pharmacol Biochem Behav 47:107–112PubMedCrossRefGoogle Scholar
  184. 184.
    Perkins KA (2001) Smoking cessation in women. Special considerations. CNS Drugs 15:391–411PubMedCrossRefGoogle Scholar
  185. 185.
    Perkins KA, Gerlach D, Vender J, Grobe J, Meeker J, Hutchison S (2001) Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res 3:141–150PubMedCrossRefGoogle Scholar
  186. 186.
    Perkins KA, Stitzer M, Lerman C (2006) Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl) 184:628–636CrossRefGoogle Scholar
  187. 187.
    Picciotto M, Zoli M, Rimondini R, Lena C, Marubio L, Pich E et al (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173–177PubMedCrossRefGoogle Scholar
  188. 188.
    Pierce J, Choi W, Gilpin E, Farkas A, Berry C (1998) Tobacco industry promotion of cigarettes and adolescent smoking. J Am Med Assoc 279:511–515CrossRefGoogle Scholar
  189. 189.
    Pierce J, Gilpin E, Choi W (1999) Sharing the blame: smoking experimentation and future smoking arributable mortality due to Joe Camel and Marlboro advertising promotions. Tobacco Control 8:37–44PubMedCrossRefGoogle Scholar
  190. 190.
    Pierce JP, Gilpin EA (2002) Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. J Am Med Assoc 288:1260–1264CrossRefGoogle Scholar
  191. 191.
    Piper ME, Fox BJ, Welsch SK, Fiore MC, Baker TB (2001) Gender and racial/ethnic differences in tobacco-dependence treatment: a commentary and research recommendations. Nicotine Tob Res 3:291–297PubMedCrossRefGoogle Scholar
  192. 192.
    Piper ME, Piasecki TM, Federman EB, Bolt DM, Smith SS, Fiore MC et al (2004) A multiple motives approach to tobacco dependence: the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). J Consult Clin Psychol 72:139–154PubMedCrossRefGoogle Scholar
  193. 193.
    Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen S et al (1992) Smoking cessation in women concerned about weight. Am J Public Health 82:1238–1243PubMedCrossRefGoogle Scholar
  194. 194.
    Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF (1994) Reliability of the Fagerstrom tolerance questionnaire and the Fagerstrom test for nicotine dependence. Addict Behav 19:33–39PubMedCrossRefGoogle Scholar
  195. 195.
    Poolsup N, Li Wan Po A, Knight TL (2000) Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 25:197–220PubMedCrossRefGoogle Scholar
  196. 196.
    Puska P, Korhonen HJ, Vartiainen E, Urjanheimo E, Gustavsson G, Westin A (1995) Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tobacco Control 4:231–235CrossRefGoogle Scholar
  197. 197.
    Rao U (2006) Links between depression and substance abuse in adolescents: neurobiological mechanisms. Am J Prev Med 31:S161–S74PubMedCrossRefGoogle Scholar
  198. 198.
    Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K et al (2006) Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188:355–363CrossRefGoogle Scholar
  199. 199.
    Rennard S, Nides M, Oncken CA, Billing CB, Reeves K, Watsky EJ et al (2006) Effects of varenicline on smoking cessation: a pooled analysis by gender. In: International Conference of the American Thoracic Society. Varenicline Study Group, San Diego, CAGoogle Scholar
  200. 200.
    Rice ME, Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 7:583–584PubMedCrossRefGoogle Scholar
  201. 201.
    Richmond RL, Harris K, de Almeida Neto A (1994) The transdermal nicotine patch: results of a randomised placebo-controlled trial. Med J Aust 161:130–135PubMedGoogle Scholar
  202. 202.
    Robins L, Helzer J, Weissman M, Orvaschel H, Gruenberg E, Burke JJ et al (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949–958PubMedCrossRefGoogle Scholar
  203. 203.
    Rose JE (1996) Nicotine addiction and treatment. Annu Rev Med 47:493–507PubMedCrossRefGoogle Scholar
  204. 204.
    Rose JE, Westman EC, Behm FM, Johnson MP, Goldberg JS (1999) Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol Biochem Behav 62:165–172PubMedCrossRefGoogle Scholar
  205. 205.
    Rose JE, Behm FM, Westman EC, Johnson M (2000) Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav 67:71–81PubMedCrossRefGoogle Scholar
  206. 206.
    Royal College of Physicians, Nicotine Addiction in Britain (2000) Royal College of Physicians, London, EnglandGoogle Scholar
  207. 207.
    Royce JM, Hymowitz N, Corbett K, Hartwell TD, Orlandi MA (1993) Smoking cessation factors among African Americans and whites. COMMIT research group. Am J Public Health 83:220–226PubMedCrossRefGoogle Scholar
  208. 208.
    Sabol S, Nelson M, Fisher C, Gunzerath L, Brody C, Hu S (1999) A genetic association for cigarette smoking behavior. Health Psychol 18:7–13PubMedCrossRefGoogle Scholar
  209. 209.
    Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA et al (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16:36–49PubMedCrossRefGoogle Scholar
  210. 210.
    Sachs DP (1995) Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch Intern Med 155:1973–1980PubMedCrossRefGoogle Scholar
  211. 211.
    Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489PubMedCrossRefGoogle Scholar
  212. 212.
    Schilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH (1998) N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781–789PubMedCrossRefGoogle Scholar
  213. 213.
    Schneider N, Lunell E, Olmstead R, Fagerstrom K (1996) Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 31:65–80PubMedCrossRefGoogle Scholar
  214. 214.
    Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A (1983) Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Behav 8:253–261PubMedCrossRefGoogle Scholar
  215. 215.
    Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME et al (1995) Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 90:1671–1682PubMedCrossRefGoogle Scholar
  216. 216.
    Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K (1996) Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 91:1293–1306PubMedCrossRefGoogle Scholar
  217. 217.
    Schnoll RA, Lerman C (2006) Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11:429–444PubMedCrossRefGoogle Scholar
  218. 218.
    Schnoll RA, Patterson F, Lerman C (2007) Treating tobacco dependence in women. J Womens Health (Larchmt) 16:1211–1218CrossRefGoogle Scholar
  219. 219.
    Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C (2002) Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20:514–520PubMedCrossRefGoogle Scholar
  220. 220.
    Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H et al (2004) Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29:1790–1799PubMedCrossRefGoogle Scholar
  221. 221.
    Shields P, Lerman C, Audrain J, Main D, Boyd N, Caporaso N (1998) Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prevent 7:453–458Google Scholar
  222. 222.
    Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379PubMedCrossRefGoogle Scholar
  223. 223.
    Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR (2002) Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162:1267–1276PubMedCrossRefGoogle Scholar
  224. 224.
    Shiffman S, Hughes JR, Di Marino ME, Sweeney CT (2003) Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction 98:1747–1753PubMedCrossRefGoogle Scholar
  225. 225.
    Shiffman S, Dresler CM, Rohay JM (2004) Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99:83–92PubMedCrossRefGoogle Scholar
  226. 226.
    Siegel M, Biener L, Rigotti NA (1999) The effect of local tobacco sales laws on adolescent smoking initiation. Prev Med 29:334–342PubMedCrossRefGoogle Scholar
  227. 227.
    Silagy C, Mant D, Fowle, R.G., Lodge M (1994) Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 343:139–142PubMedCrossRefGoogle Scholar
  228. 228.
    Silagy C, Mant D, Fowler G, Lancaster T (2001) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146Google Scholar
  229. 229.
    Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2002) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (4):CD000146Google Scholar
  230. 230.
    Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146Google Scholar
  231. 231.
    Silverman M, Neale M, Sullivan P, Harris-Kerr C, Wormley B, Sadek H (2000) Haplotypes of four novel single nucleotide polymorphisms in the nicotine acetylcholine receptor b2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. Am J Med Genet (Neuropsych Genet). 96:646–653CrossRefGoogle Scholar
  232. 232.
    Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327PubMedGoogle Scholar
  233. 233.
    Smolka MN, Buhler M, Klein S, Zimmermann U, Mann K, Heinz A et al (2006) Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl) 184:577–588CrossRefGoogle Scholar
  234. 234.
    Spitz M, Shi H, Yang F, Hudmon K, Jiang H, Chanberlain R (1998) Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358–363PubMedCrossRefGoogle Scholar
  235. 235.
    Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E et al (2006) Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 26:8707–8714PubMedCrossRefGoogle Scholar
  236. 236.
    Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146Google Scholar
  237. 237.
    Sullivan P, Kendler K (1999) The genetic epidemiology of smoking. Nicotine Tob Res 1:S51–S57PubMedCrossRefGoogle Scholar
  238. 238.
    Sullivan PF, Kendler KS (1999) The genetic epidemiology of smoking. Nicotine Tob Res 1(Suppl 2):S51–S57; discussion S69–S70PubMedCrossRefGoogle Scholar
  239. 239.
    Sun D, Ma JZ, Payne TJ, Li MD (2008) Beta-arrestins 1 and 2 are associated with nicotine dependence in European American smokers. Mol Psychiatry 13:398–406PubMedCrossRefGoogle Scholar
  240. 240.
    Sutherland G, Russell MA, Stapleton J, Feyerabend C, Ferno O (1992) Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 108:512–518PubMedCrossRefGoogle Scholar
  241. 241.
    Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC et al (2005) Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 5:21–29PubMedCrossRefGoogle Scholar
  242. 242.
    Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, McAfee T (2007) Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychology 26:361–368PubMedCrossRefGoogle Scholar
  243. 243.
    The World Health Organization (2008) WHO report on the global tobacco epidemic: the MPOWER package. World Health Organization, GenevaGoogle Scholar
  244. 244.
    Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP et al (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452:638–642PubMedCrossRefGoogle Scholar
  245. 245.
    Tochigi M, Suzuki K, Kato C, Otowa T, Hibino H, Umekage T et al (2007) Association study of monoamine oxidase and catechol-O-methyltransferase genes with smoking behavior. Pharmacogenet Genomics 17:867–872PubMedCrossRefGoogle Scholar
  246. 246.
    Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer H et al (1988) Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med 318:15–18PubMedCrossRefGoogle Scholar
  247. 247.
    Tonnesen P, Norregaard J, Simonsen K, Sawe U (1991) A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325:311–315PubMedCrossRefGoogle Scholar
  248. 248.
    Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F (1993) A double-blind trial of a nicotine inhaler for smoking cessation. Jama 269:1268–1271PubMedCrossRefGoogle Scholar
  249. 249.
    Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A et al (1999) Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European anti-smoking evaluation. European respiratory society. Eur Respiratory J 13:238–246CrossRefGoogle Scholar
  250. 250.
    Tonnesen P, Mikkelsen KL (2000) Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J 16:717–722PubMedCrossRefGoogle Scholar
  251. 251.
    Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71PubMedCrossRefGoogle Scholar
  252. 252.
    Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr et al (2007) A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 29:1027–1039PubMedCrossRefGoogle Scholar
  253. 253.
    Turner L, Mermelstein R, Flay B (2004) Individual and contextual influences on adolescent smoking. Ann NY Acad Sci 1021:175–197PubMedCrossRefGoogle Scholar
  254. 254.
    U.S. Department of Health and Human Services, Tobacco Use Among U.S. Racial/Ethnic Minority Groups. A Report of the Surgeon General. Exceutive Summary (1998) National center for chronic disease prevention and health promotion. Office on Smoking and Health, Centers for Disease ControlGoogle Scholar
  255. 255.
    U.S. Department of Health and Human Services, The Health Consequences of Smoking: A report by the Surgeon General (2004) US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GAGoogle Scholar
  256. 256.
    U.S. Food and Drug Administration. (2008) Public health advisory: center for drug evaluation and research. Important Information on Chantix (varenicline)Google Scholar
  257. 257.
    Uhl GR, Liu QR, Drgon T, Johnson CC, Walther D, Rose J et al (2008) Molecular genetics of successful smoking cessation: convergent genome-wide association results. Archiv Gen Psychiatry 65(6):683–693Google Scholar
  258. 258.
    United States Department of Health and Human Services (2008) Treating tobacco use and dependence: 2008 update. Public Health ServiceGoogle Scholar
  259. 259.
    Vandenbergh D, Bennett C, Grant M, Strasser A, O’Connor R, Stauffer R et al (2002) Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tobacco Res 4:333–340CrossRefGoogle Scholar
  260. 260.
    Voorhees CC, Stillman FA, Swank RT, Heagerty PJ, Levine DM, Becker DM (1996) Heart, body, and soul: impact of church-based smoking cessation interventions on readiness to quit. Prev Med 25:277–285PubMedCrossRefGoogle Scholar
  261. 261.
    Wagenknecht LE, Cutter GR, Haley NJ, Sidney S, Manolio TA, Hughes GH et al (1990) Racial differences in serum cotinine levels among smokers in the coronary artery risk development in (young) adults study. Am J Public Health 80:1053–1056PubMedCrossRefGoogle Scholar
  262. 262.
    West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A (2001) Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) 153:225–230CrossRefGoogle Scholar
  263. 263.
    Westman EC, Behm FM, Rose JE (1996) Dissociating the nicotine and airway sensory effects of smoking. Pharmacol Biochem Behav 53:309–315PubMedCrossRefGoogle Scholar
  264. 264.
    Wetter D, Fiore M, Jorenby D, Kenford S, Smith S, Baker T (1999) Gender differences in smoking cessation. J Counsel Clin Psychol 67:555–562CrossRefGoogle Scholar
  265. 265.
    Whiting P, Lindstrom J (1986) Pharmacological properties of immuno-isolated neuronal nicotinic receptors. J Neurosci 6:3061–3069PubMedGoogle Scholar
  266. 266.
    Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J (2007) A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 23:793–801PubMedCrossRefGoogle Scholar
  267. 267.
    World Health Organization (1992) International statistical classification of diseases and related health problems, 10th revision (ICD-10). World Health Organization, GenevaGoogle Scholar
  268. 268.
    World Health Organization (2004) Health for all statistical database. Cited 27 Feb 2007Google Scholar
  269. 269.
    Yudkin PL, Munafò M, Hey K, Roberts SJ, Welch SJ, Johnstone E et al (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Br Med J 328(7446):989–990Google Scholar
  270. 270.
    Zhang L, Kendler KS, Chen X (2006) The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct 2:28PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Freda Patterson
    • 1
  • Robert A. Schnoll
    • 1
  • Caryn Lerman
    • 1
  1. 1.Department of Psychiatry, Transdisciplinary Tobacco Use Research CenterUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations